Mouse Cancer Cell-containing Macrobeads in the Treatment of Human Cancer

This study has been completed.
Information provided by (Responsible Party):
The Rogosin Institute Identifier:
First received: January 26, 2006
Last updated: March 10, 2015
Last verified: March 2015

January 26, 2006
March 10, 2015
January 2005
December 2012   (final data collection date for primary outcome measure)
Evidence of toxicity by multiple parameters [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • Evidence of toxicity by multiple parameters
  • Tumor response (imaging, markers);
Complete list of historical versions of study NCT00283075 on Archive Site
  • Quality of life [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • Performance status [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • Progression-free survival [ Time Frame: 6 months, with tracking beyond protocol period for life ] [ Designated as safety issue: No ]
  • Tumor response (imaging, markers) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Quality of life
  • Performance status
  • Survival
Not Provided
Not Provided
Mouse Cancer Cell-containing Macrobeads in the Treatment of Human Cancer
Use of Mouse Renal Adenocarcinoma Cell-containing Agarose-agarose Macrobeads in the Treatment of Patients With End-stage, Treatment-resistant Epithelial-derived Cancer

This is a phase 1 trial to evaluate the safety and toxicity of mouse kidney cancer cell-containing agarose-agarose macrobeads that are implanted in the abdominal cavity as a proposed biological treatment of patients with end-stage, treatment-resistant cancer. The macrobeads have been extensively tested in tumor models in mice and rats, as well as in forty-five veterinary patients (cats and dogs) with naturally occurring tumors of various types including breast cancer, prostate cancer, liver cancer, and lymphoma with clear tumor responses and no significant detectable toxicity.

Cancer in its various forms continues to be a major U.S. health problem, accounting for 550,000 deaths a year, as well as much disability and suffering. Treatment for cancer has traditionally consisted of three modalities: surgery, radiation therapy, and chemotherapy. Advances with all three modalities over the years have produced long-term remissions and/or cures in certain types of cancer such as the leukemias, and prolonged survival for many other patients. Much remains to be accomplished, however, especially with respect to the treatment of solid tumors, including some of the most common cancers such as those of the lung, colon, breast, ovary, prostate and kidney. New types of less toxic and debilitating therapy are needed.

Among the therapeutic possibilities currently being explored, those that involve biological control mechanisms seem both promising and attractive. Although it has long been thought that cancer cells are not subject to the same regulatory growth control mechanisms that function in normal cells, there is a substantial body of evidence that they can respond to feedback signals telling them to slow or stop their growth. In addition, it has been determined that a relatively small population of cells within a tumor (cancer "stem" or progenitor cells) are responsible for continued tumor growth and that it is these cells that must be controlled if biological anti-tumor therapy is to be effective.

The proposed cancer treatment being tested in this Phase 1 clinical trial is based on the concept that tumor growth can be controlled by tumor mass or signals that indicate that such mass is present. In this case, however, the induction of the growth-slowing signals is brought about not by tumor mass, but by placing mouse kidney cancer cells in an agarose matrix, which both selects for cancer progenitor cells and also causes them to produce and release signals that inhibit the growth of freely growing cancer cells of the same or different type in a laboratory dish or in a tumor-bearing animal or human (i.e. is also not species-specific). This approach has proven both safe and effective in animal models and veterinary patients, and it is now in the first stage of human testing. With Phase 1 completed, we are now implementing Phase 2 efficacy trials that for the present are focused on colorectal cancer, pancreatic cancer, and prostate cancer. The Phase 1 trial remains open to a range of epithelial-derived cancer.

Phase 1
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Intraabdominal Cancers (Various Types)
Biological: Cancer Macrobead placement in abdominal cavity
8 macrobeads per kg
Other Name: cancer macrobead
Experimental: Cancer macrobeads
Cancer Macrobead placement in abdominal cavity
Intervention: Biological: Cancer Macrobead placement in abdominal cavity

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
February 2015
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • End-stage, treatment resistant epithelial-derived cancer (carcinoma) arising originally within the abdominal cavity with expected minimum six-month survival

Exclusion Criteria:

  • Multiple intraabdominal metastases or carcinomatosis or other medical conditions indicating that the procedure would be of too high a risk for the individual
18 Years to 65 Years
Contact information is only displayed when the study is recruiting subjects
United States
The Rogosin Institute
The Rogosin Institute
Not Provided
Principal Investigator: Barry H Smith, MD, PhD The Rogosin Institute
The Rogosin Institute
March 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP